Piper Sandler Upgrades ImmunityBio (NASDAQ:IBRX) to Overweight
ImmunityBio (NASDAQ:IBRX – Get Free Report) was upgraded by investment analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has a $5.00 price target on the stock, up from their previous price target of $4.25. Piper Sandler’s price objective […]
ImmunityBio (NASDAQ:IBRX – Get Free Report) was upgraded by investment analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has a $5.00 price target on the stock, up from their previous price target of $4.25. Piper Sandler’s price objective […]
